3 Reasons Cara Therapeutics Is a Better Growth Stock Than Novavax

At one point this year, Cara Therapeutics (NASDAQ: CARA) stock was up more than 175%. Most of those gains were given up, though. The stock is now up a little over 30% year to date. But that's still a better performance than Novavax (NASDAQ: NVAX) has achieved. At its peak this year, Novavax stock was up close to 30%. It's now down more than 10% year to date.

Short-term stock performance doesn't necessarily make one stock better than another. However, I think Cara Therapeutics has better growth potential than Novavax does over the near term and probably over the long run, as well. Here are three reasons why.

Image source: Getty Images.

Source: Fool.com